Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity transaction:
- Share Price: The fair market value of an Ordinary Share at the point of vesting on February 13, 2014, was £16.53.
- Transaction Value: The filing details the number of shares vested and lapsed but does not explicitly state the total monetary value of the transaction in the text provided.
Material Changes
The filing reports a specific corporate action rather than a change in operational performance. On February 13, 2014, a conditional share award made in 2011 to a connected person of a PDMR vested and lapsed based on performance conditions met over the three-year period from January 1, 2011, to December 31, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of a share plan transaction.
Important Facts for Investors
- Transaction Type: Vesting and lapping of Performance Share Plan awards under the 2009 plan.
- Parties Involved: Mr. P Thomson (PDMR) and Mrs. K Thomson (Connected Person).
- Share Details: 1,420 Ordinary Shares were awarded; 841 Ordinary Shares lapsed. The number of shares that successfully vested is not explicitly stated as a separate figure in the text, though it can be inferred as the difference between awarded and lapsed shares.
- Valuation Date: February 13, 2014.
- Regulatory Basis: Notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).